Innovative power of the pharmaceutical industry: key to Germany's prosperity!

Innovative power of the pharmaceutical industry: key to Germany's prosperity!

The health sector in Germany is currently the focus of public debate. On November 5, 2025, experts such as Médard Schoenmaeckers of Boehringer Ingelheim emphasize the crucial role that health plays in the country's resilience and economic prosperity. Innovative companies attract investments and generate new products, which is of great importance for economic stability. Loud Pharma facts The pharmaceutical industry in Germany has around 130,000 employees and contributes around 30 billion euros to gross value added per year.

But Germany is at a crossroads: the federal government has set itself the goal of developing the country into the world's most innovative location for chemistry, pharmaceuticals and biotechnology. To implement this ambitious plan, an increased focus on research and innovation is necessary. The first positive signals about this have already been noted in the coalition agreement, but skepticism remains as to whether these can actually be implemented sustainably.

Role of pharmacy in the economy

The pharmaceutical industry is seen as crucial to Germany's economic future. The upcoming federal election on February 23, 2025 will lead to increased pressure on political decision-makers to improve the framework conditions for research and development. Dorothee Brakmann, Managing Director of Pharma Germany, emphasizes how important a stable consensus among democratic parties is in order for an economic recovery to be possible. Without these supportive framework conditions, the industry would not be able to fulfill its role as a driver of economic development Pharma Germany reported in detail.

To address these challenges, Boehringer Ingelheim has published a white paper containing twelve specific suggestions that emerged from dialogues with various stakeholders. These proposals aim, among other things, to promote the importance of research in political debates and to make Germany attractive again for investments in future technologies.

Advances in research and innovation

A decisive step towards greater innovative power is the acceleration of clinical trials, which was recently initiated by the new Federal Ethics Commission at the BfArM. The approval of national study applications will be shortened from 19 days to just five - a real step forward, according to Federal Ministry of Health the approval structures are significantly simplified.

In addition, digitization in the healthcare system is being promoted to enable research on health data and to support collaborations across national borders. The government authorities are also examining funding instruments for new production facilities and are planning additional incentives for the production of medicines in the EU.

The good news is: Health is not just a cost factor, but an important investment. Long-term structural reforms in the health system are necessary to ensure Germany's competitiveness. If the actors succeed in implementing the necessary changes, Germany could be on the right track not only in the healthcare system, but also in economic terms.